Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

202.64
-2.8500-1.39%
Post-market: 202.35-0.2869-0.14%19:44 EDT
Volume:1.89M
Turnover:384.71M
Market Cap:10.26B
PE:32.10
High:204.66
Open:203.59
Low:201.92
Close:205.49
52wk High:217.12
52wk Low:138.79
Shares:50.65M
Float Shares:50.65M
Volume Ratio:1.38
T/O Rate:3.74%
Dividend:0.41
Dividend Rate:0.20%
EPS(TTM):6.31
EPS(LYR):-1.4940
ROE:24.54%
ROA:0.10%
PB:1.26
PE(LYR):-135.64

Loading ...

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08

Beneath the Surface, the Next Market Leaders are Getting Ready to Break Out, Says Morgan Stanley

Dow Jones
·
Sep 08

Ionis Pharma Tumbles After Heart Drug Fails Late-Stage Trial

Reuters
·
Sep 08

Why Amgen Stock is Dropping After Swiss Rival's Trial Setback

Dow Jones
·
Sep 08

Amgen Falls After Novartis Trial Setback, BMO Downgrade

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Amgen Shares Down 5.4% Premarket; Rival Novartis Cholesterol Drug Fails Late-Stage Study

THOMSON REUTERS
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

CSL Seeks ASX Quotation for New Shares from Employee Incentive Plan

TIPRANKS
·
Sep 08

Ceryvyn Therapeutics Plans Issue of 3 Million Long-Dated Options

TIPRANKS
·
Sep 08

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

TIPRANKS
·
Sep 08

Gilead Sciences (GILD) Receives a Buy from Bernstein

TIPRANKS
·
Sep 08